Amgen (AMGN) Tops Q2 EPS by 10c; Boosts FY16 Outlook

Amgen (NASDAQ: AMGN) reported Q2 EPS of $2.84, $0.10 better than the analyst estimate of $2.74. Revenue for the quarter came in at $5.69 billion versus the consensus estimate of $5.58 billion.

GUIDANCE:

Amgen sees FY2016 EPS of $11.10-$11.40. Amgen sees FY2016 revenue of $22.5-22.8 billion. The Street sees EPS of $11.18 and revenue of $22.57 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• BWS Financial Downgrades Inter Parfums (IPAR) to Sell